# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
New leadership in the United Kingdom could make several sectors standout going forward. Here's what experts are saying afte...
The European Medicines Agency has accepted AstraZeneca's marketing authorization application for sipavibart, an investigati...
Imfinzi plus chemotherapy as 1st-line treatment followed by Lynparza and Imfinzi has been recommended for patients with misma...
China has approved AstraZeneca's Tagrisso (osimertinib) combined with pemetrexed and platinum-based chemotherapy for first-...
AstraZeneca's ADJUVANT BR.31 Phase 3 trial reveals Imfinzi didn't meet the primary endpoint for disease-free survival i...